We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

AstraZeneca plc (AZN) 2 ADRs Rpr 1 Ord USD0.25

Sell:$55.52 Buy:$55.55 Change: $1.05 (1.86%)
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
Change: $1.05 (1.86%)
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
Change: $1.05 (1.86%)
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Contact details

1 Francis Crick Avenue
United Kingdom
+44 (20) 73045000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$173.82 billion
Shares in issue:
1.55 billion
United States
US dollar

Key personnel

  • Pascal Soriot
    Chief Executive Officer, Executive Director
  • Aradhana Sarin
    Chief Financial Officer, Executive Director
  • Jeffrey Pott
    Chief Human Resource Officer, General Counsel
  • Katarina Ageborg
    Executive Vice President - Sustainability, Chief Compliance Officer
  • Jose Baselga
    Executive Vice President - Research & Development Oncology
  • Pam Cheng
    Executive Vice President - Operations and Information Technology
  • Ruud Dobber
    Executive Vice President - BioPharmaceuticals Business
  • David Fredrickson
    Executive Vice President - Oncology Business
  • Menelas Pangalos
    Executive Vice President - Research & Development BioPharmaceuticals
  • Iskra Reic
    Executive Vice President - Europe and Canada

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.